Current and Emerging Trends in Breast Cancer: HER2+ and HER2-Low

Neil M. Iyengar, MD, discusses the use of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Yara Abdou, MD, discusses the significance of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

This publication provides a summary of key stakeholder insights on the role of antibody-drug conjugates in targeting HER2+ or HER2-low breast cancer and examines clinical trial data on treatment options for HER2+ breast cancer with brain metastases.